Dr. Daniel Curran leads Takeda’s efforts to unlock innovation and deliver transformative medicines in a variety of rare-disease areas. Dan embraces learning from, collaborating with, and meeting members of the rare disease community in an effort to produce treatments that result in better health and a brighter future for rare. 2:02 How rare disease is defined at Takeda4:10 Rare disease units at Takeda5:23 How Takeda economically justifies half of their pipeline being rare disease drugs9:06 The price of rare disease drugs is too high12:15 Why rare disease efforts are often associated with hematology14:57 What Dr. Curran enjoys about leading Takeda's rare genetics and hematology therapeutic unit16:42 Dr. Curran's professional journey20:50 Takeda's choice to support n-Lorem